Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 ProteaseReview Published on 2022-03-232023-07-02 Journal: International Journal of Molecular Sciences [Category] SARS, [키워드] drug resistance HIV-1 main protease (Mrpo) Nirmatrelvir Paxlovid PF-07321332 Protease inhibitor resistance SARS-CoV-2 [DOI] 10.3390/ijms23073507 PMC 바로가기 [Article Type] Review
Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M pro inhibitor in animal models동물 모델에서 경구용 SARS-CoV-2 M pro 억제제인 니르마트렐비르(PF-07321332)의 생식 및 발달 안전성Article Published on 2022-03-012022-09-11 Journal: Reproductive toxicology (Elmsford, N.Y.) [Category] 치료제, [키워드] administration age animal model Antiviral Clinical studies clinical study clinically coronavirus COVID-19 Critical death developmental during pregnancy Effect Embryo Embryo-Fetal development embryonic embryonic development enhancer evaluated Factor female female fertility Fertility Genetic Genetic toxicity high risk Hospitalization hospitalized patient ICH in viral infected with SARS-CoV-2 information inhibitor lack limit dose M pro male mammalian cells manifestation Nirmatrelvir NMV no effect no effects oral Oral COVID-19 therapy patient population Paxlovid PF-07321332 pharmacokinetic phase Pregnancy Prevent progression protease Protein rabbit RAT Rat. RATs Replication reported reproductive risk Ritonavir SARS-CoV-2 SARS-CoV-2 main protease selective severe disease shown specific protein the SARS-CoV-2 therapeutic option therapeutic target therapy Toxicity viral replication virus [DOI] 10.1016/j.reprotox.2022.01.006 PMC 바로가기 [Article Type] Article
Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases심장 보호 약물과 COVID-19 치료에 사용되는 약물 간의 약물 상호 작용 위험: 6개 데이터베이스의 증거 기반 검토Review Published on 2022-03-012022-09-11 Journal: Diabetes & metabolic syndrome [Category] SARS, 변종, 신약개발, 치료법, 치료제, [키워드] acting antihypertensive drugs approved Atazanavir Azithromycin cardiovascular system caution Chloroquine close monitoring comorbid condition comorbid conditions Comorbidity concomitant use COVID COVID- 19 treatment COVID-19 COVID-19 infection COVID-19 treatment database Dexamethasone diabetes dosage drug drug interaction drug-drug interaction drugs Effect Effects ENhance Evidence Factor FDA glycemic control group hypertension Hypotension Improving Infection information Interaction interaction effect life Lopinavir Lopinavir/ritonavir Medicine Medscape molnupiravir monoclonal antibodies monoclonal antibody Nirmatrelvir Patient Paxlovid polypharmacy Potential Quality of life Remdesivir resulting review risk Ritonavir therapeutic efficacy therapy treating COVID-19 Treatment worsening [DOI] 10.1016/j.dsx.2022.102451 PMC 바로가기 [Article Type] Review
Oral antivirals for the prevention and treatment of SARS-CoV-2 infectionSARS-CoV-2 감염 예방 및 치료를 위한 경구용 항바이러스제Article Published on 2022-03-012022-09-11 Journal: AIDS reviews [Category] SARS, 변종, 치료제, [키워드] advent Antiviral antiviral therapy antivirals benefit classical combination therapies combination therapy complications COVID-19 COVID-19 disease COVID-19 pandemic Disease progression dissemination Each early treatment Emergency use authorization escape mutant Formulation Infection landscape life-threatening Long-ActingAntivirals manifestation medications Medicine molnupiravir monoclonal antibodies monoclonal antibody Mutagenesis Nirmatrelvir offer oral Oral Remdesivir parenteral administration polymerase Prevent Prophylaxis protease protease inhibitors PROTECT provided reduce regulatory agencies regulatory agency Remdesivir required SARS-CoV-2 SARS-COV-2 infection severe COVID-19 disease small molecule treat Treatment Vaccine variant viral illnesses waning immunity [DOI] 10.24875/AIDSRev.22000001 PMC 바로가기 [Article Type] Article
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19Article Published on 2022-02-212023-07-08 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] COVID-19 dosage Efficacy Nirmatrelvir Paxlovid Remdesivir Ritonavir Sotrovimab Veklury
COVID-19 updates: NIH outpatient treatment guidelinesArticle Published on 2022-02-212023-07-08 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] bamlanivimab Casirivimab COVID-19 Efficacy etesevimab Imdevimab molnupiravir Nirmatrelvir Paxlovid REGEN-COV Remdesivir Ritonavir Sotrovimab Veklury
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?Perspective Published on 2022-02-092022-10-27 Journal: Antibiotics [Category] COVID-19, [키워드] ritonavir 3CL animal models antiviral drug Antiviral effect clinical trial close monitoring coronavirus COVID-19 COVID-19 pandemic dawn death demonstrated effective Effectiveness Final FIVE Hospitalization hospitalized patients inhibit M pro MPro mild case mutants Mutation Nirmatrelvir oral outpatients patients treated Paxlovid PF-07321332 protease reduction in Safe SARS-CoV-2 second spread of COVID-19 symptom onset therapy Trial Vaccine variant viral genome [DOI] 10.3390/antibiotics11020220 PMC 바로가기 [Article Type] Perspective
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernArticle Published on 2022-02-012022-10-27 Journal: Antiviral Research [Category] COVID-19, [키워드] active against Alpha Antiviral antiviral activity antivirals Beta Cell Compound conserved Delta delta variant EIDD-1931 FIVE Gamma GFP GS-441524 high-content imaging in vitro Infection molnupiravir MPro Nirmatrelvir observation omicron other variant parent nucleoside Post-infection protease Protease inhibitor Remdesivir RNA polymerase SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 serial dilution susceptible target gene target protein variants of concern Viral RNA virus VoC was determined [DOI] 10.1016/j.antiviral.2022.105252 PMC 바로가기 [Article Type] Article
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernArticle Published on 2022-02-012022-10-27 Journal: Antiviral Research [Category] Coronavirus, COVID-19, COVID19(2023년), Fulltext, SARS, [키워드] active against Alpha Antiviral antiviral activity antivirals Beta Cell Compound conserved Delta delta variant EIDD-1931 FIVE Gamma GFP GS-441524 high-content imaging in vitro Infection molnupiravir MPro Nirmatrelvir observation omicron other variant parent nucleoside Post-infection protease Protease inhibitor Remdesivir RNA polymerase SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 serial dilution susceptible target gene target protein variants of concern Viral RNA virus VoC was determined [DOI] 10.1016/j.antiviral.2022.105252 PMC 바로가기 [Article Type] Article
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concernRemdesivir, Molnupiravir 및 Nirmatrelvir는 SARS-Cov-2 Omicron 및 기타 변형에 대해 계속 활성화되어 있습니다.Article Published on 2022-02-012022-09-10 Journal: Antiviral Research [Category] 변종, 치료제, [키워드] active against Alpha Antiviral antiviral activity antivirals Beta Cell Compound conserved Delta delta variant Delta variants determined by EIDD-1931 FIVE Gamma GFP GS-441524 high-content imaging Highlights in vitro Infection molnupiravir MPro Nirmatrelvir nucleoside observation omicron other variant parent nucleoside Post-infection protease Protease inhibitor Remdesivir RNA polymerase SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV2 serial dilution serial dilutions susceptible target gene Target genes target protein target proteins variants variants of concern Viral Viral RNA virus VoC was determined [DOI] 10.1016/j.antiviral.2022.105252 PMC 바로가기 [Article Type] Article